Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 RE

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio...

Related Keywords

Ann Arbor ,Michigan ,United States ,Spain ,Madrid ,Hall Goya ,Kristenm Pettit ,Corey Davis ,Division Of Hematology Oncology ,Department Of Internal Medicine ,Network Of Companies ,University Of Michigan ,European Hematology Association ,Protagonist Therapeutics Inc ,Nasdaq ,Protagonist Therapeutics ,Presentation Title ,Updated Long Term Results ,Study Investigating ,Hepcidin Mimetic Rusfertide ,Polycythemia Vera Patients ,Hematocrit Control ,Therapeutic Phlebotomy ,Internal Medicine ,Conference Session ,Abstract Details ,Hepcidin Mimetic ,Polycythemia Vera ,Nishit Modi ,Clinical Pharmacology ,